COVID-19 and management of neuroimmunological disorders

Nat Rev Neurol. 2020 Jul;16(7):347-348. doi: 10.1038/s41582-020-0368-9.

Abstract

The importance of reported neurological manifestations of coronavirus disease 2019 (COVID-19) is still unclear. Nevertheless, an immediate and ongoing neurological challenge posed by the COVID-19 pandemic is the management of patients who are undergoing immunotherapy for existing neuroimmunological disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Betacoronavirus*
  • COVID-19
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / immunology*
  • Coronavirus Infections / therapy*
  • Disease Management*
  • Humans
  • Immunotherapy / methods
  • Nervous System Diseases / epidemiology
  • Nervous System Diseases / immunology*
  • Nervous System Diseases / therapy*
  • Neuroimmunomodulation / physiology
  • Pandemics
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / immunology*
  • Pneumonia, Viral / therapy*
  • SARS-CoV-2